Jane S. Vergnes, Ph.D., DABT®

Director of Toxicology


Director of Toxicology for B&C® Consortia Management, L.L.C. (BCCM), Dr. Vergnes provides BCCM's clients with toxicology expertise for the broad range of research, testing, regulatory, and advocacy goals our consortium members seek. An experienced leader in global product stewardship, she offers clients an agile, multi-disciplinary talent for problem-solving honed in her 25 years directing product stewardship and toxicology departments for Ashland, Inc., International Specialty Products (ISP), Texaco, and Union Carbide (now Dow).  Dr. Vergnes is also an experienced research scientist and scientific study director with a Ph.D. in Human Genetics and a specialization in the genetic/epigenetic modes of action of toxicants, and she deploys the full depth of her scientific, business, and policy knowledge to resolve clients' challenges.

Articles and Writings

  • Bevan, C., Gargas, M., Kirman, C., and Vergnes, J.  2009.  “Mode of Action and Derivation of a Cancer and Non-cancer Reference Value for 4-Vinylcyclohexene.” Toxicologist 108(1).

  • Vergnes, J.S. and Ballantyne, B.  2002.  “Genetic Toxicology Studies with Glutaraldehyde.”  J. Appl. Toxicol. 22:45-60.

  • Vergnes, J.S. and Ballantyne, B.  2001.  “In Vitro and in Vivo Genetic Toxicology Studies with Diethylene Glycol Monohexyl Ether.”  J. Appl. Toxicol. 21: 449-460.

  • Vergnes, J.S. and Ballantyne, B.  2000.  “2,4-Pentanedione: Evaluation of the Genotoxic Potential in Vitro and in Vivo.”  Toxic Substance Mechanisms 19:151-175.

B&C, Acta, and BCCM provide a full range of global support for the commercialisation of chemicals, biocides, and products of industrial biotechnology, nanotechnology, and synthetic biology.

View Our Services


  • BA, Ohio Wesleyan University, Bacteriology, 1974
  • Ph.D., University of Pittsburgh, Human Genetics, 1982